{
    "clinical_study": {
        "@rank": "53566", 
        "acronym": "IGPC-3", 
        "arm_group": {
            "arm_group_label": "18F-FCH PET/MRI imaging", 
            "arm_group_type": "Other", 
            "description": "Patients eligible for the study will have an 18F-FCH PET/MRI in addition to standard of care clinical assessment and imaging (CT and bone scan)"
        }, 
        "brief_summary": {
            "textblock": "Evaluate the impact of hybrid 18F-Fluoro-choline (18F-FCH) PET/MRI imaging on the clinical\n      management of men with suspected recurrent prostate cancer post prostatectomy.\n\n      We hypothesize that hybrid imaging incorporating 18F-FCH PET/MRI imaging will be feasible\n      and will lead to changes in management decisions among men being re-staged for suspected\n      prostate cancer recurrence post-surgery who are potentially eligible for local salvage\n      therapy."
        }, 
        "brief_title": "Prospective Study Using Hybrid PET/MRI to Evaluate Men With Suspected Recurrence Following Treatment for Prostate Cancer", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Neoplasms", 
                "Recurrence"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will be a non-randomized, prospective study of men with suspected local recurrence\n      of prostate cancer post-prostatectomy with negative bone and CT scans.  Hybrid PET/MRI using\n      18F-FCH will be obtained and a consensus staging report generated for the attending\n      clinician.  Clinical management questionnaires completed by the study investigator will be\n      obtained pre and post imaging in order to gauge the impact of the hybrid imaging on clinical\n      decision making."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Prostate cancer with rising prostate specific antigen (PSA) post prostatectomy\n\n          -  Suspected recurrence based on PSA rise measured on 3 occasions at least 3 months\n             apart and an absolute PSA > 0.2 ng/mL\n\n          -  Bone scan and CT scan of the abdomen and pelvis negative for metastatic disease\n\n        Exclusion Criteria:\n\n          -  Evidence of metastatic disease\n\n          -  Contradiction to 18F-FCH PET scan\n\n          -  Contraindication to MRI"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01804231", 
            "org_study_id": "IGPC-3", 
            "secondary_id": "CTP-87515"
        }, 
        "intervention": {
            "arm_group_label": "18F-FCH PET/MRI imaging", 
            "description": "Patients will first undergo screening to ensure eligibility.  If eligible, they will undergo one scan in a Hybrid PET/MRI scanner using 18F-FCH as the radiolabeled tracer.", 
            "intervention_name": "18F-FCH PET/MRI imaging", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prostate Cancer", 
            "PET", 
            "MRI", 
            "Hybrid", 
            "Recurrence", 
            "Fluorocholine"
        ], 
        "lastchanged_date": "May 1, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "N6A 5W9"
                }, 
                "name": "London Health Sciences Centre"
            }, 
            "investigator": [
                {
                    "last_name": "Glenn Bauman, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Joseph Chin, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jonathan Izawa, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Steven Pautler, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Alp Sener, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nicholas Power, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Belal Ahmed, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "George Rodrigues, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael Lock, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Tracey Sexton, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "David D'Souza, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "V.M. Venkatesan, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective Study of Hybrid PET/MRI in the Evaluation of Men With Suspected Prostate Cancer Recurrence Following Definitive Local Therapy", 
        "other_outcome": {
            "description": "Lesions identified on the 18F-FCH MRI/PET will be examined to determine what proportion of lesions are present on both MRI and PET imaging versus what proportion of lesions are present on only one of MRI or PET", 
            "measure": "Concordance between MRI and 18F-FCH PET for lesion identification", 
            "safety_issue": "No", 
            "time_frame": "Within 2 weeks of study scan"
        }, 
        "overall_contact": {
            "email": "ashley.lozanski@lhsc.on.ca", 
            "last_name": "Ashley Lozanski, H.BSc., CCRP", 
            "phone": "519-685-8500", 
            "phone_ext": "57349"
        }, 
        "overall_official": {
            "affiliation": "London Health Sciences Centre", 
            "last_name": "Dr. Glenn S Bauman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Canada: Ethics Review Committee", 
                "Canada: Canadian Institutes of Health Research"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A questionnaire to assess the planned management will be completed by the investigator before and after provision of the results of the 18F-FCH PET/MRI to determine if the information provided by 18F-FCH PET/MRI influences the preferred plan of management", 
            "measure": "Frequency in change of clinical management based on results of 18F-FCH PET/MRI", 
            "safety_issue": "No", 
            "time_frame": "Within 2 weeks of study scan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01804231"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Lawson Health Research Institute", 
            "investigator_full_name": "Glenn Bauman", 
            "investigator_title": "Chair/Chief of the Department of Oncology at the Schulich School of Medicine and Dentistry, University of Western Ontario", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Number of lesions identified with 18F-FCH based on consensus reporting", 
            "safety_issue": "No", 
            "time_frame": "Within 2 weeks of study scan"
        }, 
        "source": "Lawson Health Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Canadian Institutes of Health Research  (CIHR)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Lawson Health Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}